How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
Eisenberger
M A
MA
Nelson
W G
WG
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D013498:Suramin / Q000494:pharmacology* / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D013498:Suramin; D017430:Prostate-Specific Antigen